Market News

FDA Clears Investigational NDA for Sonnet’s SON-1010; Shares Skyrocket

Shares of the biopharmaceutical company Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) rose around 87% at Wednesday’s close. The surge in price followed the company’s announcement that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) Application for SON-1010 to treat advanced solid tumors. 

SON-1010 is a proprietary version of Interleukin 12 (IL-12), which is designed using Sonnet’s Fully Human Albumin Binding (FHAB) technology. The regulator’s clearance permits the company to commence its first-of-its-kind Phase 1 trial in adult oncology patients in the second quarter of 2022. 

As per the company’s press release, the Phase 1 trial is designed for the “evaluation of the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of SON-1010 in adult patients” suffering from advanced solid tumors. It will be a multiple ascending dose study.  

CEO’s Comments 

Encouraged by the FDA approval, Sonnet CEO Pankaj Mohan said, “We are excited about the progress we have made with our FHAB platform, which we believe will set the stage for improved efficacy of monospecific and bispecific cytokines, each differentiated by tumor targeting and retention in the tumor microenvironment.” 

Wall Street’s Take 

Following the FDA’s clearance, Chardan Capital analyst Keay Nakae maintained a Buy rating and a price target of $2.50 (385.44% upside potential) on the stock.  

Nakae views the FDA’s clearance as a “significant milestone for the company”. 

Consensus among analysts is a Strong Buy based on three unanimous Buys. The average Sonnet price target of $2.17 implies 321.36% upside potential from current levels. Shares have lost 18.25% over the past six months. 


TipRanks’ Stock Investors tool shows that investors currently have a Very Positive stance on Sonnet, with 20.1% of investors maintaining portfolios on TipRanks increasing their exposure to SONN stock over the past 30 days.

Download the TipRanks mobile app now 

To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. 

Read full Disclaimer & Disclosure 

Related News: 
Ford to Expand EV Footprint in Europe 
ExxonMobil Fails to Rescind Appeal to Terminate Climate Change Investigations 
Intel to Invest €80B to Expand Footprint in European Union

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More